Page last updated: 2024-08-26

sr141716 and Abdominal Obesity

sr141716 has been researched along with Abdominal Obesity in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Rosenson, RS	1
Brown, MW; Deanfield, JE; Després, JP; Job, B; Kastelein, JJ; Nissen, SE; O'Leary, DH; Reuwer, AQ; Visseren, FL; Zabbatino, SM; Zhou, R	1
Di Marzo, V; Silvestri, C	1

Reviews

2 review(s) available for sr141716 and Abdominal Obesity

Article	Year
Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk. Cardiology, 2009, Volume: 114, Issue:3 Topics: Animals; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Clinical Trials as Topic; Endocannabinoids; Humans; Mental Disorders; Obesity, Abdominal; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors	2009
Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert opinion on investigational drugs, 2012, Volume: 21, Issue:9 Topics: Animals; Cannabinoid Receptor Antagonists; Drug Design; Drug Inverse Agonism; Endocannabinoids; Humans; Metabolic Diseases; Obesity, Abdominal; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors	2012

Article

Year

Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk.

Cardiology, 2009, Volume: 114, Issue:3

Topics: Animals; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Clinical Trials as Topic; Endocannabinoids; Humans; Mental Disorders; Obesity, Abdominal; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors

2009

Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.

Expert opinion on investigational drugs, 2012, Volume: 21, Issue:9

Topics: Animals; Cannabinoid Receptor Antagonists; Drug Design; Drug Inverse Agonism; Endocannabinoids; Humans; Metabolic Diseases; Obesity, Abdominal; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors

2012

Trials

1 trial(s) available for sr141716 and Abdominal Obesity

Article	Year
Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. Heart (British Cardiac Society), 2011, Volume: 97, Issue:14 Topics: Anti-Obesity Agents; Canada; Carotid Arteries; Carotid Artery Diseases; Chi-Square Distribution; Disease Progression; Double-Blind Method; Europe; Female; Humans; Kaplan-Meier Estimate; Male; Metabolic Syndrome; Obesity, Abdominal; Piperidines; Placebo Effect; Prospective Studies; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography; United States; Waist Circumference; Weight Loss	2011

Article

Year

Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial.

Heart (British Cardiac Society), 2011, Volume: 97, Issue:14

Topics: Anti-Obesity Agents; Canada; Carotid Arteries; Carotid Artery Diseases; Chi-Square Distribution; Disease Progression; Double-Blind Method; Europe; Female; Humans; Kaplan-Meier Estimate; Male; Metabolic Syndrome; Obesity, Abdominal; Piperidines; Placebo Effect; Prospective Studies; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography; United States; Waist Circumference; Weight Loss

2011